Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Saggi, Studi e Ricerche

N. 54 (2020)

Hepatitis C management and treatment among people who inject drugs in Italy: an exploratory pilot survey.

DOI
https://doi.org/10.3280/mis54-2020oa9744
Inviata
8 maggio 2020
Pubblicato
10-12-2020

Abstract

Background

People Who Use Drugs (PWID) play a crucial role in the goal of eradicating hepatitis C and, despite the high efficacy and tolerability of Direct Acting Antivirals, many PWID still have to be treated and there are many barriers that slow down the process. An exploratory pilot survey was conducted to determine service providers' current condition and the barriers experienced by PWID in accessing HCV treatment. 

 

Methods

Seven selected clinical centres completed a 27-item online survey addressing the current treatment situation in PWID hepatitis C treatment, related barriers and linkage to care. 

 

Result

The survey mainly involved central-northern Italian clinical centres (71.4%), with less than 4 prescribers (71.4%) despite they are currently treating around 500-1000 patients for Hepatitis C (>50% current or former PWID). In most cases, they carried out the necessary checks (100% blood sample, 85.7% fibroscan and 43% ultrasound) in few visits (85.7%) to deliver drugs in about one month (71.4%). They all agree on the need for fast-track for PWID and therefore they are all engaged in dedicated projects. The commitment to eradication is, in most cases, based on personal efforts, which despite the few prescribers, the lack of institutional support (85.7%) and the impossibility to use simplification scores since prescription and drug delivery portals (AIFA and regional) still require a lot of information. Although the centres questioned express the need for a simplification of the bureaucratic processes, however, they scrupulously follow PWID. For 57.4% of the centres, Linkage to Care remains the most problematic moment, to follow equally the lack of a correct epidemiological estimate and the implementation of the harm reduction policies. Finally, most of the centres don’t find particular barriers related to PWID’s features, but analysing them individually the main ones are: the difficult social background, the reinfection risk and the patient’s poor motivation.

Conclusions

The needs emerged from this survey are: to work on PWID de-stigmatization, to simplify the prescription/drug delivery portals in order, to increase PWID social assistance network and institutions support in HCV eradication programs. 

 

Riferimenti bibliografici

  1. Agenzia Italiana del Farmaco. Registri AIFA DAAs – Epatite C cronica, uffici registri di monitoraggio, 03/02/2020. www.aifa.gov.it/documents/20142/847506/Aggiornamento_dati_Registri_AIFA_DAAs-03-02-2020.pdf/a2474474-bf00-e737-23a0-58fe11eb7143.
  2. AASLD, IDSA (2020). Key Populations: Identification and Management of HCV in People Who Inject Drugs. www.HCVGuidance.org on January 30.
  3. Cunningham E.B., Amin J., Feld J.J., Bruneau J., Dalgard O., Powis J., Hellard M., Cooper C., Read P., Conway B., Dunlop A.J., Norton B., Litwin A.H., Hajarizadeh B., Thurnheer M.C., Dillon J.F., Weltman M., Shaw D., Bruggmann P., Gane E., Fraser C., Marks P., Applegate T.L., Quiene S., Siriragavan S., Matthews G.V., Dore G.J., Grebely J., SIMPLIFY study group (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. Int J Drug Policy, Dec, 62: 14-23. doi: 10.1016/j.drugpo.2018.08.013.
  4. Dillon J.F., Lazarus J.V., Razavi H.A. (2016). Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy., Jun 30, 1: 2. doi: 10.1186/s41124-16-0011-y.
  5. Dore G.J., Altice F., Litwin A.H., Dalgard O., Gane E.J., Shibolet O., Luetkemeyer A., Nahass R., Peng C.Y., Conway B., Grebely J., Howe A.Y., Gendrano I.N., Chen E., Huang H.C., Dutko F.J., Nickle D.C., Nguyen B.Y., Wahl J., Barr E., Robertson M.N., Platt H.L., C-EDGE CO-STAR Study Group (2016). Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med., Nov 1, 165(9): 625-634. doi: 10.7326/M16-0816.
  6. European Monitoring Centre for Drugs and Drug Addition (EMCDDA) (2019). Hepatitis C: models of care for drug services in Europe. www.emcdda.europa.eu/system/files/attachments/11482/Hepatitis-C-new-models-of-care-for-drugs-services_WEB.pdf.
  7. European Monitoring Centre for Drugs and Drug Addition (EMCDDA) (2019). Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe. www.emcdda.europa.eu/system/files/publications/11796/Technical%20report_The%20elimination%20barometer%20for%20viral%20hepatitis%20among%20PWID%20in%20Europe_0.pdf.
  8. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2019, trends and developments. www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf.
  9. Flamm S., Mutimer D., Asatryan A., Wang S., Rockstroh J., Horsmans Y., Kwo P.Y., Weiland O., Villa E., Heo J., Gane E., Ryder S.D., Welzel T.M., Ruane P.J., Agarwal K., Ng T.I., Xue Z., Lovell S.S., Krishnan P., Kopecky-Bromberg S., Trinh R., Mensa F.J., Wyles D.L. (2019). Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. J Viral Hepat., Mar., 26(3): 337-349. doi: 10.1111/jvh.13038.
  10. Fourati S., Feld J.J., Chevaliez S., Luhmann N. (2018). Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc., Apr, 21(Suppl. 2): e25058. doi: 10.1002/jia2.25058.
  11. Franco R.A., Galbraith J.W., Overton E.T. (2018). Saag MS. Direct-acting antivirals and chronic hepatitis C: towards elimination. Hepatome Res, 4: 74. doi: 10.20517/2394-5079.2018.94.
  12. Grebely J., Sherman K.E., Baumgarten A., Conway B., Jackson D., Asselah T., Gschwantler M., Tomasiewicz K., Aguilar H., Asatryan A., Hu Y., Mensa F.J. (2019). Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend., Jan 1, 194: 487-494. doi: 10.1016/j.drugalcdep.2018.11.007.
  13. Grebely J., Dore G.J., Morin S., Rockstroh J.K., Klein M.B. (2017). Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? J Int AIDS Soc., 20(1): 22146. doi: 10.7448/IAS.20.1.22146.
  14. Grebely J., Oser M., Taylor L.E., Dore G.J. (2013). Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIVcoinfection: action required at the system, provider, and patient levels. J Infect Dis., Mar, 207(Suppl. 1): S19-25. doi: 10.1093/infdis/jis928.
  15. Grebely J., Haire B., Taylor L.E., Macneill P., Litwin A.H., Swan T. et al. (2015). Excluding people who use drugs or alcohol from access to hepatitis C treatments – is this fair, given the available data? J Hepatol., 63: 779-82.
  16. Grebely J., Dore G.J., Zeuzem S. et al. (2016). Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis., 63(11): 1479-1481.
  17. Grebely J., Hajarizadeh B., Dore G.J. (2017). Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol., 14(11): 641-651.
  18. Harris M., Jolly E., Martin A., Wells H., Rhodes T. (2012), Barriers and facilitators to Hepatitis C treatment for People who inject drugs A qualitative study, June. www.euro.who.int/__data/assets/pdf_file/0011/179750/Barriers-and-facilitators-to-hepatitis-C-treatment-for-PWID-A-qualitative-study-June-2012-rev-5.pdf.
  19. Kattakuzhy S., Mathur P., Gross C. et al. (2018). High SVR in PWID with HCV despite imperfect medication adherence: data from the anchor study. Hepatology, 68(S1). doi: 10.1002/hep.30256.
  20. Kattakuzhy S., Gross C., Emmanuel B., Teferi G., Jenkins V., Silk R., Akoth E., Thomas A., Ahmed C., Espinosa M., Price A., Rosenthal E., Tang L., Wilson E., Bentzen S., Masur H., Kottilil S. (2017). Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-BasedNonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med., Sep 5, 167(5): 311-318. doi: 10.7326/M17-0118.
  21. Lazarus J.V., Sperle I., Maticic M., Wiessing L. (2014). A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis., 14(Suppl. 6): S16. doi: 10.1186/1471-2334-14-S6-S16.
  22. Lazarus J.V., Safreed-Harmon K., Thursz M.R., Dillon J.F., El-Sayed M.H., Elsharkawy A.M., Hatzakis A., Jadoul M., Prestileo T., Razavi H., Rockstroh J.K., Wiktor S.Z., Colombo M. (2018). The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Semin Liver Dis., Aug, 38(3): 181-192. doi: 10.1055/s-0038-1666841.
  23. Litwin A.H., Drolet M., Nwankwo C., Torrens M., Kastelic A., Walcher S., Somaini L., Mulvihill E., Ertl J., Grebely J. (2019). Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepat., Sep, 26(9): 1094-1104. doi: 10.1111/jvh.13119. Epub 2019 Jun 11.
  24. Marinho R.T., Barreira D.P. (2013). Hepatitis C, stigma and cure. World J Gastroenterol, 19: 6703-9.
  25. Stein J.A., Nyamathi A. (2004). Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend, 75: 89-95.
  26. Maticic M., Videcnik Zorman J., Gregorcic S., Schatz E., Lazarus J.V. (2019). Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct Journal, May, 9, 16(1): 32. doi: 10.1186/s12954-019-0303-9.
  27. Molinaro S., Resce G., Alberti A., Andreoni M., D’Egidio P.P.F., Leonardi C., Nava F.A., Pasqualetti P., Villa S. (2019). Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. Drug Alcohol Rev., Sep, 38(6): 644-655. doi: 10.1111/dar.12978.
  28. Murdock M., Brizzi M.B., Perez O., Badowski M.E. (2019). Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review. Infect Dis Ther, 8: 23-32. doi: 10.1007/s40121-018-0228-8.
  29. Norton B.L., Fleming J., Bachhuber M.A., Steinman M., DeLuca J., Cunningham C.O., Johnson N., Laraque F., Litwin A.H. (2017). Int J Drug Policy, 47: 196-201.
  30. Palmateer N., Hutchinson S., McAllister G., Munro A., Cameron S., Goldberg D., Taylor A. (2014). Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat, Jan, 21(1): 25-32. doi: 10.1111/jvh.12117.
  31. Stein J.A., Andersen R.M., Robertson M., Gelberg L. (2012). Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen behavioral model for vulnerable populations. Health Psychol, 31: 20-30.
  32. Terrault N.A. (2019). Hepatitis C elimination: challenges with underdiagnosis and under-treatment. F1000Res., Jan 14, 8, pii: F1000 Faculty Rev-54. doi: 10.12688/f1000research.15892.1.
  33. World Health Organization Europe (2017). Action plan for the health sector response to viral hepatitis in the WHO European region. www.euro.who.int/data/assets/pdf_file/0008/357236/Hepatitis-9789289052870-eng.pdf.
  34. Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., EMCDDA DRID group, Hatzakis A., Prins M., Vickerman P., Lazarus J.V., Hope V.D., Matheï C. (2014). Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS One, 9(7): e103345. doi: 10.1371/journal.pone.0103345.

Metriche

Caricamento metriche ...